Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jiangsu Hengrui Pharmaceuticals Co's enterprise value is ¥243,610 Mil.
Jiangsu Hengrui Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥8,615 Mil. Therefore, Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA for today is 28.28.
SHSE:600276'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 27.36 Med: 53.38 Max: 86.13
Current: 28.28
During the past 13 years, the highest EV-to-EBITDA of Jiangsu Hengrui Pharmaceuticals Co was 86.13. The lowest was 27.36. And the median was 53.38.
SHSE:600276's EV-to-EBITDA is ranked worse than 78.74% of 729
companies
in the Drug Manufacturers industry
Industry Median: 13.27
vs SHSE:600276: 28.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Hengrui Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Hengrui Pharmaceuticals Co's share price for today is ¥42.67.
Jiangsu Hengrui Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA falls into.
Jiangsu Hengrui Pharmaceuticals Co's current Enterprise Value is ¥243,610 Mil.
Jiangsu Hengrui Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥8,615 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a EV-to-EBITDA of 28.28 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Hengrui Pharmaceuticals Co. This is 47% below median its historical median of 53.38. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA has ranged from 27.36 to 86.13. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #574 out of 729 companies in the Drug Manufacturers industry, placing it in the top 78.7%.
Is Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA too high?
Jiangsu Hengrui Pharmaceuticals Co's current EV-to-EBITDA of 28.28 is 47% below median its 10-year median of 53.38. Over the past 10 years, this metric has ranged from a low of 27.36 to a high of 86.13. The Drug Manufacturers industry median EV-to-EBITDA is 13.27. Jiangsu Hengrui Pharmaceuticals Co's value of 28.28 is 113.1% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #574 out of 729 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #574 out of 729 companies for EV-to-EBITDA. This places Jiangsu Hengrui Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.27. Jiangsu Hengrui Pharmaceuticals Co's value of 28.28 is 113.1% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own EV-to-EBITDA has ranged from 27.36 to 86.13 over the past decade. While the company's 10-year median is 53.38 vs. the industry median of 13.27, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.27, based on 729 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current EV-to-EBITDA of 28.28 is 113.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Hengrui Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current EV-to-EBITDA is 28.28, which is 47% below median its own 10-year median of 53.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥58.42, compared to a current price of ¥42.67 — trading 27% below its estimated fair value. The current EV-to-EBITDA is 28.28, which is 47% below median its 10-year median of 53.38 and 113.1% above the Drug Manufacturers industry median of 13.27. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current EV-to-EBITDA is 28.28 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥42.67 is trading 27% below its estimated GF Value™ of ¥58.42.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
EV-to-EBITDA: 28.28 (47% below median its 10-year median of 53.38)
GF Value™: ¥58.42 vs. price of ¥42.67 (27% below fair value)
Industry Position: 113.1% above the Drug Manufacturers median (#574 of 729)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
90GF Score
Get the complete analysis for SHSE:600276
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
